Vishay Intertechnology Insider Sold Shares Worth $597,096, According to a Recent SEC Filing-July 2024-www.financetom.com

Vishay Intertechnology Insider Sold Shares Worth $597,096, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Vishay Intertechnology Insider Sold Shares Worth $597,096, According to a Recent SEC Filing

Mar 6, 2024 6:29 AM

09:07 AM EST, 03/06/2024 (MT Newswires) -- Marc Zandman, Director, ExecChairman & Chief Bus Dev, on March 04, 2024, sold 26,154 shares in Vishay Intertechnology ( VSH ) for $597,096. Following the Form 4 filing with the SEC, Zandman has control over a total of 73,678 shares of the company, with 73,678 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/103730/000010373024000059/xslF345X03/form4.xml

Previous page： Thyssenkrupp cuts sales, profit forecasts amid gloomy market Next page： Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Thyssenkrupp cuts sales, profit forecasts amid gloomy market

May 15, 2024

* Now expects net loss vs break even in 2023/24 * Books impairments on materials trading division * Thyssenkrupp shares -5.7%, Thyssenkrupp Nucera -8% (Adds details on tariff discussion in paragraph) By Christoph Steitz and Tom Käckenhoff FRANKFURT, May 15 (Reuters) - German conglomerate Thyssenkrupp cut its annual forecasts for sales and net profit for the second time in three...

Biogen Partner Eisai Submits FDA Biologics Application for Early Alzheimer's Self-Injection Drug

May 15, 2024

04:26 AM EDT, 05/15/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Tuesday that the latter has initiated a rolling submission of a biologics license application to the US Food and Drug Administration for lecanemab-irmb subcutaneous autoinjector as a weekly maintenance treatment for early Alzheimer's disease. The application came after the treatment, commercially known as Leqembi, was granted FDA fast-track...

Novonix Signs Testing, Development Deal With Volkswagen-Owned PowerCo

May 15, 2024

04:32 AM EDT, 05/15/2024 (MT Newswires) -- Novonix ( NVX ) said late Tuesday it signed a non-exclusive testing and development agreement with Volkswagen-owned PowerCo to come up with synthetic graphite anode materials for electric vehicle batteries. The companies could later enter into a supply agreement for the products developed under the deal, Novonix ( NVX ) said. Financial terms...

Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket

May 15, 2024

04:24 AM EDT, 05/15/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) Arcutis Biotherapeutics' ( ARQT ) shares surged more than 20% in premarket activity on Wednesday after the company reported a narrower loss and handily beat market expectations for sales. The company reported a Q1 loss late Tuesday of $0.32 per diluted...